New developments in therapy of deep mycoses

Japanese Journal of Medical Mycology

Volumn 41, Issue 4, 2000, Pages 221-228

  Yamaguchi, H ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

(antifungal azole); (antifungal chemotherapy); (antifungal lipopeptide); (clinical development); (lipid formulation); B (amphotericin B)

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; JK 1211; MICAFUNGIN; MICONAZOLE; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRIMIDINE DERIVATIVE; RAVUCONAZOLE; SM 26000; TRIAZOLE DERIVATIVE; UK 292663; UNCLASSIFIED DRUG; VORICONAZOLE;

ASCOMYCETES; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DRUG STRUCTURE; FUSARIUM; MYCOSIS; OPPORTUNISTIC INFECTION; REVIEW; TRICHOSPORON; ZYGOMYCETES;

ASCOMYCOTA; ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; FILOBASIDIELLA NEOFORMANS; FUSARIUM; PSEUDALLESCHERIA BOYDII; ZYGOMYCETES;

EID: 0033669026     PISSN: 09164804     EISSN: None     Source Type: Journal    
DOI: 10.3314/jjmm.41.221     Document Type: Review

References (59)

1. Amphotericins A and B, antifungal antibiotics produced by Streptomycete. I in vitro studies
2. Antifungal agents: Chemotherapeutic targets and immunologic strategies
3. New approaches to antifungal chemotherapy
4. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients
5. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablet in the treatment of esophageal candidiasis
6. Efficacy, safety, and pharmacokinetlcs of intravenous (IV) followed by oral itraconazole (ITR) in patients (pts) with invasive pulmonary aspergillosis (IPA)
7. Current and emerging azole antifungal agents
8. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
9. In vitro activities of voriconazole (UK-109,486) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection
10. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive aspergillosis
11. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications
12. In vitro evaluation of voriconazole against some clinically important fungi
13. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
14. In vitro activity of voriconazole against Candida species
15. Vorlconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species
16. In vitro activities of voriconazole (UK- 109, 496) and four other antifungal agents against 394 clinical isolates of Candida spp
17. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates
18. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei
19. The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells
20. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin
21. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens
22. Efficacy of UK-109,496, a new azole antifungal agent, in an experimental model of invaslve aspergillosis
23. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
24. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp
25. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts
26. Comparison of in vitro activities of the new triazole SCH56592 and the echinoeandins MK-0991 (L-743,872) and LY 303366 against opportunistic filamentous and dimorphic fungi and yeasts
27. In vitro and in vivo efficacy of the azole SCH 56592 against Cryptococcus neoformans
28. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus
29. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis
30. SCH56592 treatment of murine invasive aspergillosis
31. Fungicidal mechanisms of action of D0870 against Cryptococcus neoformans under acidic conditions
32. A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis
33. The use of lipid formulations of amphotericin B for systemic fungal infections
34. Lipid-based amphotericin B for the treatment of fungal infections
35. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (Am Bisome) in neutropenic patients
36. A randomized comparison Of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
37. Treatment of mycotic infections after haematopoietic progenitor cell transplantation with liposomal amphotericin-B
38. Liposomal amphotericin B for empiric therapy in patients with persistent fever and neutropenia
39. Liposomal amphotericin B (Am Bisome) in the prophylaxis of fungal infections in neutropenic patients a randomized, double-blind, placebo-controlled study
40. Lipid nano-sphere (LNS), a protein-free analogue of lipoproteins, as a novel drug carrier for parenteral administration IV
41. A new antifungal drug delivery system, lipid nanosphere encapsulating amphotericin B (LNS-Am B): Its evaluation in the rat model of invasive pulmonary aspergillosis
42. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans
43. Antifungal peptides: Novel therapeutic compounds against emerging pathogens
44. Fungal cell wall inhibitors; emphasis on clinical aspects
45. Antifungal agents chemotherapeutic targets and immunologic strategies
46. Lipopeptide inhibitors of fungal glucan synthase
47. Echinocandin antifungal agents
48. Novelties in the field of anti-infectives in 1998
49. In vitro activities of a new lipopeptide antifungal agent, against a variety of clinically important fungi
50. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis
51. Efficacy of FK463, a new llpopeptide antifungal agent, in mouse models of pulmonary aspergillosis
52. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens